Fractyl Health (GUTS) officer awarded 845,226 stock options at $2.24
Rhea-AI Filing Summary
Fractyl Health, Inc. reported that one of its officers, serving as President and Chief Product Officer, received a stock option grant on 12/15/2025. The option covers 845,226 shares of common stock at an exercise price of $2.24 per share and expires on 12/14/2035.
According to the disclosure, the option vests and becomes exercisable in equal installments on each of the first three anniversaries of the grant date, as long as the officer remains employed through each vesting date. Following this grant, the officer beneficially owns 845,226 derivative securities, held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Caplan Jay David
Role
President, Chief Product Off.
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 845,226 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 845,226 shares (Direct)
Footnotes (1)
- F1. The stock option vests and becomes exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the Reporting Persons's continuing in employment through each such vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Fractyl Health (GUTS) report in this Form 4?
The company reported a stock option grant to an officer, covering 845,226 shares of Fractyl Health, Inc. common stock as a derivative security.
What is the exercise price of the options granted at Fractyl Health (GUTS)?
The stock option has an exercise price of $2.24 per share for the underlying common stock.
When was the Fractyl Health (GUTS) stock option grant made and when does it expire?
The option grant date is 12/15/2025, and the option expires on 12/14/2035.
How do the Fractyl Health (GUTS) options vest for this officer?
The stock option vests in equal installments on each of the first three anniversaries of the 12/15/2025 grant date, subject to the officer continuing in employment through each vesting date.
What role does the reporting person hold at Fractyl Health (GUTS)?
The reporting person is an officer of Fractyl Health, Inc., serving as President, Chief Product Officer.
How many derivative securities does the Fractyl Health (GUTS) officer own after the transaction?
After this reported transaction, the officer beneficially owns 845,226 derivative securities (stock options), held directly.